All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-11

AUTHORS

Adedayo Adedoyin, Dwight D. Stiff, David C. Smith, Marjorie Romkes, Robert C. Bahnson, Roger Day, Janie Hofacker, Robert A. Branch, Donald L. Trump

ABSTRACT

PURPOSE: All-trans-retinoic acid (ATRA) is a retinoid analogue that has been shown to be effective in acute promyelocytic leukemia. It is currently being investigated for efficacy in the treatment and prevention of various types of cancer. One of the factors limiting its use is the observed increase in ATRA clearance and elimination which occurs shortly after treatment is started, leading to reduced levels of drug in the body and loss of effectiveness. ATRA efficacy may be enhanced if this autoinduction of metabolism can be overcome, for example through the inhibition of the activity of the induced specific metabolizing enzyme(s). This requires the identification of this induced enzyme(s) and development of approaches to selectively inhibit its activity. METHODS: In the course of a phase II evaluation of ATRA in prostate cancer, we investigated the activities of five specific cytochrome P450 (CYP) (CYPs 1A2, 2C19, 2D6, 2E1 and 3A4) and N-acetyltransferase enzymes using a newly developed five-drug cocktail involving caffeine, mephenytoin, debrisoquine, chlorzoxazone and dapsone respectively. Enzyme activities were assessed in 17 patients with hormone-refractory prostate cancer before the initiation of ATRA therapy, after 14 days of continuous ATRA administration and 7 days after cessation of drug therapy. RESULTS: After 14 days of ATRA therapy, the activities of CYP2E1 (chlorzoxazone hydroxylase) and N-acetyltransferase (in fast acetylators only) were increased by 83% and 29% (P < 0.05), respectively. Both activities returned to baseline by 7 days after cessation of therapy and the profiles were similar to the changes seen in the clearance of ATRA itself. There were no changes in the activities of any of the other enzymes investigated. CONCLUSION: This study shows that ATRA selectively modulates the activities of specific metabolizing enzymes and that this approach may be useful in identifying enzymes that can be explored in an attempt to mitigate ATRA autoinduction through selective modulation of enzyme activities. Further investigations are required to determine whether the elevated enzymes are also responsible for the increased clearance and elimination of ATRA. More... »

PAGES

133-139

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050719

DOI

http://dx.doi.org/10.1007/s002800050719

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033936341

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9443626


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 Enzyme System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tretinoin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412689.0", 
          "name": [
            "Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adedoyin", 
        "givenName": "Adedayo", 
        "id": "sg:person.01363745125.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363745125.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412689.0", 
          "name": [
            "Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stiff", 
        "givenName": "Dwight D.", 
        "id": "sg:person.0756105572.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756105572.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "David C.", 
        "id": "sg:person.015706665604.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412689.0", 
          "name": [
            "Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Romkes", 
        "givenName": "Marjorie", 
        "id": "sg:person.01115201742.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115201742.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bahnson", 
        "givenName": "Robert C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Day", 
        "givenName": "Roger", 
        "id": "sg:person.012525045577.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012525045577.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh", 
          "id": "https://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofacker", 
        "givenName": "Janie", 
        "id": "sg:person.0762522245.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762522245.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412689.0", 
          "name": [
            "Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Branch", 
        "givenName": "Robert A.", 
        "id": "sg:person.01315631725.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315631725.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trump", 
        "givenName": "Donald L.", 
        "id": "sg:person.0710021450.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0378-4347(95)00380-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002365050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1990.204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010607395", 
          "https://doi.org/10.1038/clpt.1990.204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90102-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017139339"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90102-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017139339"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.88.12.5237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019744066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/347773a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027331824", 
          "https://doi.org/10.1038/347773a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0003-9861(84)90353-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037047033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1984.256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037303884", 
          "https://doi.org/10.1038/clpt.1984.256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(00)84078-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039931892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199307153290307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048208053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199406000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199406000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199406000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199502000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289354"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199502000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289354"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-199502000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060289354"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-11", 
    "datePublishedReg": "1997-11-01", 
    "description": "PURPOSE: All-trans-retinoic acid (ATRA) is a retinoid analogue that has been shown to be effective in acute promyelocytic leukemia. It is currently being investigated for efficacy in the treatment and prevention of various types of cancer. One of the factors limiting its use is the observed increase in ATRA clearance and elimination which occurs shortly after treatment is started, leading to reduced levels of drug in the body and loss of effectiveness. ATRA efficacy may be enhanced if this autoinduction of metabolism can be overcome, for example through the inhibition of the activity of the induced specific metabolizing enzyme(s). This requires the identification of this induced enzyme(s) and development of approaches to selectively inhibit its activity.\nMETHODS: In the course of a phase II evaluation of ATRA in prostate cancer, we investigated the activities of five specific cytochrome P450 (CYP) (CYPs 1A2, 2C19, 2D6, 2E1 and 3A4) and N-acetyltransferase enzymes using a newly developed five-drug cocktail involving caffeine, mephenytoin, debrisoquine, chlorzoxazone and dapsone respectively. Enzyme activities were assessed in 17 patients with hormone-refractory prostate cancer before the initiation of ATRA therapy, after 14 days of continuous ATRA administration and 7 days after cessation of drug therapy.\nRESULTS: After 14 days of ATRA therapy, the activities of CYP2E1 (chlorzoxazone hydroxylase) and N-acetyltransferase (in fast acetylators only) were increased by 83% and 29% (P < 0.05), respectively. Both activities returned to baseline by 7 days after cessation of therapy and the profiles were similar to the changes seen in the clearance of ATRA itself. There were no changes in the activities of any of the other enzymes investigated.\nCONCLUSION: This study shows that ATRA selectively modulates the activities of specific metabolizing enzymes and that this approach may be useful in identifying enzymes that can be explored in an attempt to mitigate ATRA autoinduction through selective modulation of enzyme activities. Further investigations are required to determine whether the elevated enzymes are also responsible for the increased clearance and elimination of ATRA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800050719", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438856", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2471531", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "41"
      }
    ], 
    "name": "All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes", 
    "pagination": "133-139", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a1a9f61c5338236978aa13c96c1dde1daed32843458e85c67e698c839f406473"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9443626"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050719"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033936341"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050719", 
      "https://app.dimensions.ai/details/publication/pub.1033936341"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs002800050719"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050719'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050719'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050719'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050719'


 

This table displays all metadata directly associated to this object as RDF triples.

223 TRIPLES      21 PREDICATES      52 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050719 schema:about N1b5d5819703849ca86c0c64df3fbf696
2 N360c9010036b4b2fb2d7d049beebe826
3 N54f411a3cd134bb2805975d96928af77
4 N775138ece8ff4106b25420da4817c29f
5 N7ccc0fb01e184af1b3c5f550393299f0
6 N86e57a3575194f98aaed14e556eb1f04
7 N9fe79f1d2ff2445fb3ca3d3d5740e4b5
8 Nb613f8be188143c29a952c903909501b
9 Ncb0f32762ea3408cbff8c70a27fba4ec
10 Nd03d62cd8f44413e806f4d1e788e8475
11 Nddc5e3dd35f04743af3fce2f49f16ddf
12 Nfe3e3ea7801c479fa58507dea84f6c15
13 anzsrc-for:11
14 anzsrc-for:1115
15 schema:author N8928028990e047138eed6e1ab968e5cc
16 schema:citation sg:pub.10.1038/347773a0
17 sg:pub.10.1038/clpt.1984.256
18 sg:pub.10.1038/clpt.1990.204
19 https://doi.org/10.1016/0003-9861(84)90353-9
20 https://doi.org/10.1016/0006-2952(87)90102-x
21 https://doi.org/10.1016/0378-4347(95)00380-0
22 https://doi.org/10.1016/s0378-4347(00)84078-5
23 https://doi.org/10.1056/nejm199307153290307
24 https://doi.org/10.1073/pnas.88.12.5237
25 https://doi.org/10.1097/00008571-199406000-00001
26 https://doi.org/10.1097/00008571-199502000-00001
27 schema:datePublished 1997-11
28 schema:datePublishedReg 1997-11-01
29 schema:description PURPOSE: All-trans-retinoic acid (ATRA) is a retinoid analogue that has been shown to be effective in acute promyelocytic leukemia. It is currently being investigated for efficacy in the treatment and prevention of various types of cancer. One of the factors limiting its use is the observed increase in ATRA clearance and elimination which occurs shortly after treatment is started, leading to reduced levels of drug in the body and loss of effectiveness. ATRA efficacy may be enhanced if this autoinduction of metabolism can be overcome, for example through the inhibition of the activity of the induced specific metabolizing enzyme(s). This requires the identification of this induced enzyme(s) and development of approaches to selectively inhibit its activity. METHODS: In the course of a phase II evaluation of ATRA in prostate cancer, we investigated the activities of five specific cytochrome P450 (CYP) (CYPs 1A2, 2C19, 2D6, 2E1 and 3A4) and N-acetyltransferase enzymes using a newly developed five-drug cocktail involving caffeine, mephenytoin, debrisoquine, chlorzoxazone and dapsone respectively. Enzyme activities were assessed in 17 patients with hormone-refractory prostate cancer before the initiation of ATRA therapy, after 14 days of continuous ATRA administration and 7 days after cessation of drug therapy. RESULTS: After 14 days of ATRA therapy, the activities of CYP2E1 (chlorzoxazone hydroxylase) and N-acetyltransferase (in fast acetylators only) were increased by 83% and 29% (P < 0.05), respectively. Both activities returned to baseline by 7 days after cessation of therapy and the profiles were similar to the changes seen in the clearance of ATRA itself. There were no changes in the activities of any of the other enzymes investigated. CONCLUSION: This study shows that ATRA selectively modulates the activities of specific metabolizing enzymes and that this approach may be useful in identifying enzymes that can be explored in an attempt to mitigate ATRA autoinduction through selective modulation of enzyme activities. Further investigations are required to determine whether the elevated enzymes are also responsible for the increased clearance and elimination of ATRA.
30 schema:genre research_article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N3100c8d2fcd34b60bb3d071446fe000d
34 Ne4b06bcb1e224e2b937103ab6494e18b
35 sg:journal.1088364
36 schema:name All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes
37 schema:pagination 133-139
38 schema:productId N0a884b13949941fa8c4739e0c044c0b1
39 N29912646fd9646b8a6a43a0e782eb3d1
40 N317589f2af224494912c962bc8600b9c
41 N429eb2d93f4d48e1bfd36ef4092b85c5
42 N75adf1665db04f23bb314dd039b802f2
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033936341
44 https://doi.org/10.1007/s002800050719
45 schema:sdDatePublished 2019-04-11T02:01
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher N557fac2931ba40d5809b4a1954ea04f8
48 schema:url http://link.springer.com/10.1007%2Fs002800050719
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N0a884b13949941fa8c4739e0c044c0b1 schema:name doi
53 schema:value 10.1007/s002800050719
54 rdf:type schema:PropertyValue
55 N0d9c4114b6b94b979bf9f820ea71905b rdf:first sg:person.0762522245.51
56 rdf:rest Nf1cda8b5678b42e199d5e395ada72fc5
57 N158c87fb4f7c4738a590f6152f99438e rdf:first sg:person.0756105572.33
58 rdf:rest N87b6aef47c8e4e51be9d97589b3a5f64
59 N17356801c07547708993fffa0e995c25 rdf:first N4848bb1995584c39adebffbaf8443e26
60 rdf:rest N1f2e0828d7504cb98caf282bc46e0919
61 N1b5d5819703849ca86c0c64df3fbf696 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Metabolic Clearance Rate
63 rdf:type schema:DefinedTerm
64 N1f2e0828d7504cb98caf282bc46e0919 rdf:first sg:person.012525045577.12
65 rdf:rest N0d9c4114b6b94b979bf9f820ea71905b
66 N208315d7de7449d085174840add555f7 schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
67 rdf:type schema:Organization
68 N29912646fd9646b8a6a43a0e782eb3d1 schema:name nlm_unique_id
69 schema:value 7806519
70 rdf:type schema:PropertyValue
71 N3100c8d2fcd34b60bb3d071446fe000d schema:issueNumber 2
72 rdf:type schema:PublicationIssue
73 N317589f2af224494912c962bc8600b9c schema:name readcube_id
74 schema:value a1a9f61c5338236978aa13c96c1dde1daed32843458e85c67e698c839f406473
75 rdf:type schema:PropertyValue
76 N360c9010036b4b2fb2d7d049beebe826 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Prostatic Neoplasms
78 rdf:type schema:DefinedTerm
79 N429eb2d93f4d48e1bfd36ef4092b85c5 schema:name dimensions_id
80 schema:value pub.1033936341
81 rdf:type schema:PropertyValue
82 N4848bb1995584c39adebffbaf8443e26 schema:affiliation N75b57cd1ea9a4290adf35556c8915059
83 schema:familyName Bahnson
84 schema:givenName Robert C.
85 rdf:type schema:Person
86 N54f411a3cd134bb2805975d96928af77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Adenocarcinoma
88 rdf:type schema:DefinedTerm
89 N557fac2931ba40d5809b4a1954ea04f8 schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N69ffd919f6814edb804e3e6e126838c7 rdf:first sg:person.0710021450.77
92 rdf:rest rdf:nil
93 N75adf1665db04f23bb314dd039b802f2 schema:name pubmed_id
94 schema:value 9443626
95 rdf:type schema:PropertyValue
96 N75b57cd1ea9a4290adf35556c8915059 schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
97 rdf:type schema:Organization
98 N775138ece8ff4106b25420da4817c29f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Cytochrome P-450 Enzyme System
100 rdf:type schema:DefinedTerm
101 N7ccc0fb01e184af1b3c5f550393299f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Enzyme Inhibitors
103 rdf:type schema:DefinedTerm
104 N86e57a3575194f98aaed14e556eb1f04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Drug Interactions
106 rdf:type schema:DefinedTerm
107 N87b6aef47c8e4e51be9d97589b3a5f64 rdf:first sg:person.015706665604.37
108 rdf:rest N9cb94e9b2f2946c4a4a10b6ee44fc598
109 N8928028990e047138eed6e1ab968e5cc rdf:first sg:person.01363745125.74
110 rdf:rest N158c87fb4f7c4738a590f6152f99438e
111 N98b8886d42a949caaa3adba0c56e8c5d schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
112 rdf:type schema:Organization
113 N9cb94e9b2f2946c4a4a10b6ee44fc598 rdf:first sg:person.01115201742.25
114 rdf:rest N17356801c07547708993fffa0e995c25
115 N9fe79f1d2ff2445fb3ca3d3d5740e4b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Phenotype
117 rdf:type schema:DefinedTerm
118 Nb613f8be188143c29a952c903909501b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Male
120 rdf:type schema:DefinedTerm
121 Ncb0f32762ea3408cbff8c70a27fba4ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Cytochrome P-450 Enzyme Inhibitors
123 rdf:type schema:DefinedTerm
124 Nd03d62cd8f44413e806f4d1e788e8475 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 Nd2cec58b79014c96a62c4b42e3393f5d schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
128 rdf:type schema:Organization
129 Nddc5e3dd35f04743af3fce2f49f16ddf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Tretinoin
131 rdf:type schema:DefinedTerm
132 Ne4b06bcb1e224e2b937103ab6494e18b schema:volumeNumber 41
133 rdf:type schema:PublicationVolume
134 Nf1cda8b5678b42e199d5e395ada72fc5 rdf:first sg:person.01315631725.62
135 rdf:rest N69ffd919f6814edb804e3e6e126838c7
136 Nfe3e3ea7801c479fa58507dea84f6c15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antineoplastic Agents
138 rdf:type schema:DefinedTerm
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
143 schema:name Pharmacology and Pharmaceutical Sciences
144 rdf:type schema:DefinedTerm
145 sg:grant.2438856 http://pending.schema.org/fundedItem sg:pub.10.1007/s002800050719
146 rdf:type schema:MonetaryGrant
147 sg:grant.2471531 http://pending.schema.org/fundedItem sg:pub.10.1007/s002800050719
148 rdf:type schema:MonetaryGrant
149 sg:journal.1088364 schema:issn 0344-5704
150 1432-0843
151 schema:name Cancer Chemotherapy and Pharmacology
152 rdf:type schema:Periodical
153 sg:person.01115201742.25 schema:affiliation https://www.grid.ac/institutes/grid.412689.0
154 schema:familyName Romkes
155 schema:givenName Marjorie
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115201742.25
157 rdf:type schema:Person
158 sg:person.012525045577.12 schema:affiliation N208315d7de7449d085174840add555f7
159 schema:familyName Day
160 schema:givenName Roger
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012525045577.12
162 rdf:type schema:Person
163 sg:person.01315631725.62 schema:affiliation https://www.grid.ac/institutes/grid.412689.0
164 schema:familyName Branch
165 schema:givenName Robert A.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315631725.62
167 rdf:type schema:Person
168 sg:person.01363745125.74 schema:affiliation https://www.grid.ac/institutes/grid.412689.0
169 schema:familyName Adedoyin
170 schema:givenName Adedayo
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363745125.74
172 rdf:type schema:Person
173 sg:person.015706665604.37 schema:affiliation N98b8886d42a949caaa3adba0c56e8c5d
174 schema:familyName Smith
175 schema:givenName David C.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37
177 rdf:type schema:Person
178 sg:person.0710021450.77 schema:affiliation Nd2cec58b79014c96a62c4b42e3393f5d
179 schema:familyName Trump
180 schema:givenName Donald L.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77
182 rdf:type schema:Person
183 sg:person.0756105572.33 schema:affiliation https://www.grid.ac/institutes/grid.412689.0
184 schema:familyName Stiff
185 schema:givenName Dwight D.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756105572.33
187 rdf:type schema:Person
188 sg:person.0762522245.51 schema:affiliation https://www.grid.ac/institutes/grid.21925.3d
189 schema:familyName Hofacker
190 schema:givenName Janie
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762522245.51
192 rdf:type schema:Person
193 sg:pub.10.1038/347773a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027331824
194 https://doi.org/10.1038/347773a0
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/clpt.1984.256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037303884
197 https://doi.org/10.1038/clpt.1984.256
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/clpt.1990.204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010607395
200 https://doi.org/10.1038/clpt.1990.204
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/0003-9861(84)90353-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037047033
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/0006-2952(87)90102-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017139339
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/0378-4347(95)00380-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002365050
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0378-4347(00)84078-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039931892
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1056/nejm199307153290307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048208053
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1073/pnas.88.12.5237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019744066
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1097/00008571-199406000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060289319
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1097/00008571-199502000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060289354
217 rdf:type schema:CreativeWork
218 https://www.grid.ac/institutes/grid.21925.3d schema:alternateName University of Pittsburgh
219 schema:name Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA, US
220 rdf:type schema:Organization
221 https://www.grid.ac/institutes/grid.412689.0 schema:alternateName University of Pittsburgh Medical Center
222 schema:name Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
223 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...